HHS, DOD boost superbug fight with $97M investment: 4 things to know

Mackenzie Bean - Print  | 

Federal officials upped their fight against superbugs with a $97 million investment into antibiotic development.  

Four things to know:

 1. HHS and the U.S. Department of Defense partnered with VenatoRx Pharmaceuticals to develop an antibiotic that can treat highly resistant infections, such as carbapenem-resistant Enterobacteriaceae.

 2. VenatoRx has an antibiotic candidate that has shown promise against antibiotic-resistant infections when combined with cefepime, an antibiotic already on the market. The combination could be used as an intravenous treatment for drug-resistant gram-negative infections.

 3. HHS' Biomedical Advanced Research and Development Authority will offer up to $20.7 million over two years to fund the drug's development through a cost-sharing agreement. Funding may be expanded to $86.8 million over six years.

 4. The DOD's Defense Threat Reduction Agency will also provide $10 million to fund research into whether the antibiotic candidate could protect against biothreat bacterial pathogens.

More articles on clinical leadership and infection control:
Jewish Hospital to suspend heart transplant program
Kansas requires meningitis, hep A vaccines for school-aged children
2 injured in explosion at Connecticut hospital

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.